CU23977B1 - CHEMICAL PEPTIDE OF TRYPANOSOMA CRUZI - Google Patents

CHEMICAL PEPTIDE OF TRYPANOSOMA CRUZI

Info

Publication number
CU23977B1
CU23977B1 CU20100016A CU20100016A CU23977B1 CU 23977 B1 CU23977 B1 CU 23977B1 CU 20100016 A CU20100016 A CU 20100016A CU 20100016 A CU20100016 A CU 20100016A CU 23977 B1 CU23977 B1 CU 23977B1
Authority
CU
Cuba
Prior art keywords
trypanosoma cruzi
chimeric
antigen
chemical peptide
synthetic peptide
Prior art date
Application number
CU20100016A
Other languages
Spanish (es)
Other versions
CU20100016A7 (en
Inventor
Marín Milenen María Hernández
Spengler Idialis Hernández
Cordero Ivonne Gómez
León María Elena Selles
Arenas Martha Teonila Amat
Original Assignee
Ct De Inmunoensayo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunoensayo filed Critical Ct De Inmunoensayo
Priority to CU20100016A priority Critical patent/CU23977B1/en
Publication of CU20100016A7 publication Critical patent/CU20100016A7/en
Publication of CU23977B1 publication Critical patent/CU23977B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Péptido sintético quimérico obtenido mediante síntesis química en fase sólida, que contiene secuencias inmunodominantes del Trypanosoma cruzi, causante del mal de Chagas. La antigenicidad del péptido quimérico fue superior al de los péptidos monoméricos por separado, además de que puede ser utilizado como antígeno para detectar anticuerpos contra más de una proteína simultáneamente. El péptido sintético quimérico puede ser usado como antígeno en ensayos para la detección de anticuerpos específicos al Trypanosoma cruzi, en la certificación de la sangre de donantes y en la vigilancia epidemiológica.Chimeric synthetic peptide obtained by solid-phase chemical synthesis, which contains immunodominant sequences from Trypanosoma cruzi, which causes Chagas disease. The antigenicity of the chimeric peptide was superior to that of the monomeric peptides separately, in addition to that it can be used as an antigen to detect antibodies against more than one protein simultaneously. The chimeric synthetic peptide can be used as an antigen in assays for the detection of antibodies specific to Trypanosoma cruzi, in the certification of donor blood and in epidemiological surveillance.

CU20100016A 2010-01-28 2010-01-28 CHEMICAL PEPTIDE OF TRYPANOSOMA CRUZI CU23977B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20100016A CU23977B1 (en) 2010-01-28 2010-01-28 CHEMICAL PEPTIDE OF TRYPANOSOMA CRUZI

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20100016A CU23977B1 (en) 2010-01-28 2010-01-28 CHEMICAL PEPTIDE OF TRYPANOSOMA CRUZI

Publications (2)

Publication Number Publication Date
CU20100016A7 CU20100016A7 (en) 2012-06-21
CU23977B1 true CU23977B1 (en) 2014-01-29

Family

ID=46514992

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20100016A CU23977B1 (en) 2010-01-28 2010-01-28 CHEMICAL PEPTIDE OF TRYPANOSOMA CRUZI

Country Status (1)

Country Link
CU (1) CU23977B1 (en)

Also Published As

Publication number Publication date
CU20100016A7 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
CY1120976T1 (en) TWO SPECIFIC IGG ANTIBODIES AS TYP CELL ACTIVATING FACTORS
AR101669A1 (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
AR101400A1 (en) INDIVIDUAL CHAIN INDIVIDUAL CHAIN ANTIBODY CONSTRUCTION WITH IMPROVED FABRIC DISTRIBUTION
CL2016002840A1 (en) Compositions comprising aav expressing dual antibody constructs and their uses
MX2017007826A (en) Fusion protein comprising three binding domains to 5t4 and cd3.
CY1120707T1 (en) ANTI-CD28 HUMANIZED ANTIBODIES
MX2018009386A (en) Psma and cd3 bispecific t cell engaging antibody constructs.
GT201300306A (en) ANTI-ANGPTL3 ANTIBODIES AND USES OF THE SAME
CL2013001645A1 (en) Isolated nucleic acid sequence encoding a chimeric antigen receptor, which comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region and a cd3 zeta signaling domain; said receiver; cell; vector; and its use to treat a disease related to the elevated expression of a tumor antigen.
MX2020001450A (en) COMPOSITIONS FOR REDUCING IMMUNOSUPPRESSION BY TUMOR CELLS.
UY35484A (en) Single chain binding molecule comprising N-end ABP
AR080301A1 (en) ANTIBODIES AND IMMUNOCONJUGADOS OF FOLATO RECEIVER 1 AND ITS USES
PE20180042A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM
MX2018002400A (en) CONDITIONALLY ACTIVE CHEMICAL ANTIGENS RECEIVERS FOR MODIFIED T-CELLS.
CR20130609A (en) ELIMINATION OF DIANA CELLS BY VIRUS SPECIFIC CYTOTOXIC T-CELLS USING COMPLEXES THAT INCLUDE CLASS 1 MHC
ES2670621T3 (en) Antibodies that bind to OX40 and its uses
MX2021000435A (en) BISPECIFIC MOLECULES THAT ARE IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS THAT EXPRESS AN ACTIVATOR RECEPTOR AND AN ANTIGEN EXPRESSED BY A CELL INFECTED BY A VIRUS AND USES THEREOF.
EA201400108A1 (en) OPTIONS OF POLYPEPTIDES AND THEIR APPLICATIONS
CL2012000806A1 (en) Anti-guanylyl cyclase c antibody (gcc); immunoconjugate of said antibody; cell, vector and method of production; composition comprising the antibody, use of the antibody or composition for preparing a medicament for treating cancer, particularly of the gastrointestinal system.
GT201300113A (en) POLYPEPTIDES THAT LINK TO CXCR2
CU20170023A7 (en) ANTIBODIES AND RECEIVERS OF CHEMICAL ANTIGENS SPECIFIC TO CD19
MX386422B (en) LABELED CHEMICAL EFFECTOR MOLECULES AND THEIR RECEPTORS.
EA201490070A1 (en) Glucagon Receptor / GLP-1-Receptor Coantagonists
MX2015009594A (en) Antibody constructs for cdh19 and cd3.
AR076106A1 (en) ANTI-CD40 ANTIBODIES AND USES OF THE SAME

Legal Events

Date Code Title Description
FG Grant of patent